← Eichor
Study identifier: NCT04170634 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Tumoral Bone Strength Assessment by Numerical Simulation Using Quantitative CT : the MEKANOS Study

Condition: Metastases to Bone · Metastatic Breast Cancer · Metastatic NSCLC  ·  Sponsor: Hospices Civils de Lyon

PhaseN/A
Planned participants220
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Osteolytic bone metastases and myeloma bone lesions are responsible of long bone and vertebral fractures leading to restricted mobility, surgery and medullar compression that severely alter quality of life and that have a huge medico-economic impact. It has been estimated that 50% of the patients with bone metastasis will encounter bone complications. In the recent years, Bone Oncology Multidisciplinary Meetings have been developed to optimize bone metastases management for each patient in harmony with oncology program. The assessment of the fracture risk of bone metastasis remains fairly empirical and is based on simple radiography. The Mirel's score for long bones is focused on the extent of cortical defect caused by bone metastasis to identify high-risk patients at risk of fracture during surgery. It is old, little used in routine and lacks sensitivity and specificity. The SINS (Spinal Instability Neoplastic Score) score is the reference for vertebrae. Today, most patients with fracture-risk bone metastasis benefit from a lesion-centered CT scan to better characterize its extent and position but the interpretation remains qualitative. Metastases are considered as an air cavity and the mechanical properties of the tumor are not evaluated. However, many other parameters from the CTscan are available such as cortical or trabecular compartment densitometry, cortical thickness, tumor volume, and position of lysis in the bone. Based on experience acquired by the service in the…

This description comes directly from the study's public registry record.

Talk to the study team

Cyrille CONFAVREUX, PR  ·  4.78.86.12.31  ·  cyrille.confavreux@chu-lyon.fr

Sara CALATTINI  ·  4.78.86.37.79  ·  sara.calattini@chu-lyon.fr

Always discuss trial participation with your own doctor first.

Locations (12)

Service de rhumatologie, CHU d'AngersAngers, FranceRecruiting
Ch Annecy GenevoisAnnecy, FranceRecruiting
Service de radiothérapie, Institut Jean-PerrinClermont-Ferrand, FranceRecruiting
Service de rhumatologie, CH AnnemasseContamine-sur-Arve, FranceRecruiting
Service d'onco-rhumatologie, Centre Oscar LombretLille, FranceRecruiting
Service de Radiothérapie, Centre Léon Bérard, 28 Prom. Léa et Napoléon BullukianLyon, FranceRecruiting
Service d'oncologie médicale, Institut Curie, 26 rue d'UlmParis, FranceRecruiting
Service de Radiologie, Hôpital Cochin, Assistance Publique - Hôpitaux de ParisParis, FranceRecruiting
Service de Rhumatologie, Hospices Civils de Lyon, Groupement Hospitalier Lyon SudPierre-Bénite, FranceRecruiting
Service de rhumatologie, CHU de PoitiersPoitiers, FranceRecruiting
Service de rhumatologie, CHU de Saint EtienneSaint-Priest-en-Jarez, FranceRecruiting
Institut de Cancérologie de LorraineVandœuvre-lès-Nancy, FranceRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04170634